Q4 2020 13F Holders as of 12/31/2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
7.94M
-
Number of holders
-
51
-
Total 13F shares, excl. options
-
9.74M
-
Shares change
-
+229K
-
Total reported value, excl. options
-
$62.6M
-
Value change
-
+$1.45M
-
Number of buys
-
25
-
Number of sells
-
-15
-
Price
-
$6.43
Significant Holders of X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR) as of Q4 2020
54 filings reported holding XFOR - X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share as of Q4 2020.
X4 Pharmaceuticals, Inc - Common Stock, par value $0.001 per share (XFOR) has 51 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 9.74M shares
.
Largest 10 shareholders include Bain Capital Life Sciences Investors, LLC (1.65M shares), ORBIMED ADVISORS LLC (1.09M shares), BlackRock Inc. (1.03M shares), Ikarian Capital, LLC (826K shares), BVF INC/IL (793K shares), AXA S.A. (569K shares), RA CAPITAL MANAGEMENT, L.P. (537K shares), STATE STREET CORP (410K shares), New Leaf Venture Partners, L.L.C. (335K shares), and Polaris Venture Management Co. V, L.L.C. (311K shares).
This table shows the top 51 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.